Heart Failure with Preserved Ejection Fraction
📧 Sign up to get email alerts when something new happens for Heart Failure with Preserved Ejection Fraction.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction [Phase 4]
Phase 4 clinical trial updating the effects of empagliflozin on left atrial function in heart failure with preserved or mildly reduced eject…
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction [Phase 4]
A Phase 4 clinical trial comparing catheter-based ablation of atrial fibrillation to conventional treatment in patients with heart failure w…
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Improving Metabolic Health in Patients With Diastolic Dysfunction [NA]
A completed clinical trial from UT Southwestern investigating metabolic health improvements in patients with diastolic dysfunction, obesity,…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction [Phase 4]
Phase 4 trial evaluating the effects of empagliflozin on gut microbiota in patients with heart failure with preserved ejection fraction.
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease [Phase 2]
Phase 2 long-term study assessing macitentan for heart failure with preserved ejection fraction and pulmonary vascular disease. The trial wa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction [NA]
A completed clinical trial evaluated neuromodulation for treating heart failure with preserved ejection fraction; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-09-15Clinical Trial Update: A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) [Phase 2]
Phase 2 trial assessing the effect of IW-1973 on exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF).
-
CLINICAL_TRIALS withdrawal · 2022-07-28Clinical Trial Update: Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction [Phase 4]
A Phase 4 trial evaluating ferric carboxymaltose for iron deficiency in heart failure with preserved ejection fraction has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing [NA]
Clinical trial update on pulmonary congestion assessment during cardiac hemodynamic stress testing; study terminated with results posted in …
-
CLINICAL_TRIALS research · 2022-07-15Clinical Trial Update: Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction) [NA]
A completed clinical trial evaluating exercise intolerance in elderly patients with heart failure with preserved ejection fraction (HFpEF).
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Exercise Pulmonary Transit Time [Phase 4]
Phase 4 clinical trial update on Exercise Pulmonary Transit Time in heart failure with preserved ejection fraction; results posted.
-
CLINICAL_TRIALS trial_result · 2022-06-06Clinical Trial Update: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) [Phase 3]
EMPEROR-Preserved is a Phase 3 trial evaluating empagliflozin in patients with heart failure with preserved ejection fraction; results have …
-
CLINICAL_TRIALS withdrawal · 2022-05-10Clinical Trial Update: Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus [Phase 4]
A Phase 4 trial evaluating Polydiuretic Therapy for heart failure with preserved ejection fraction and diabetes mellitus has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease [Phase 2]
Phase 2 study assessing macitentan as a safety and efficacy treatment for heart failure with preserved ejection fraction and pulmonary vascu…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure [Phase 4]
A Phase 4 trial on personalizing treatment for pulmonary hypertension associated with diastolic heart failure was terminated; results were p…
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction [Phase 4]
Phase 4 trial update on circulating NEP and NEP inhibition in heart failure with preserved ejection fraction (HFpEF).
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus [Phase 4]
Phase 4 trial assessing the impact of empagliflozin on exercise capacity and left ventricular diastolic function in patients with heart fail…
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction [Phase 3]
Phase 3 trial evaluating dapagliflozin on exercise capacity in heart failure with preserved ejection fraction; results posted after completi…
-
CLINICAL_TRIALS trial_result · 2021-10-22Clinical Trial Update: The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF [Phase 2]
Phase 2 clinical trial investigating the effect of an angiotensin receptor-neprilysin inhibitor on cardiac fibrosis in patients with heart f…
-
CLINICAL_TRIALS withdrawal · 2021-08-30Clinical Trial Update: Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction [Phase 3]
Phase 3 trial investigating sacubitril/valsartan for myocardial oxygenation and fibrosis in heart failure with preserved ejection fraction w…
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study [NA]
A feasibility study on adherence to adaptive servo-ventilation therapy in patients with heart failure with preserved (normal) ejection fract…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Effect of Dapagliflozin on LV Remodeling Post AMI [Phase 4]
Phase 4 clinical trial update investigating the effect of dapagliflozin on left ventricular remodeling after myocardial infarction.
-
CLINICAL_TRIALS trial_result · 2021-03-02Clinical Trial Update: β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR) [Phase 4]
Phase 4 trial assessing withdrawal of β-blockers in patients with heart failure with preserved ejection fraction and chronotropic incompeten…
-
CLINICAL_TRIALS trial_result · 2021-02-17Clinical Trial Update: Heart Function in Patients Assessed for Sleep Apnoea
A completed clinical trial updating heart function in patients assessed for sleep apnea; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-12Clinical Trial Update: Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED) [Phase 2]
Phase IIb trial updating safety and efficacy across four dose regimens of BAY1021189 in patients with heart failure with preserved ejection …